cagrisema vs semaglutide CagriSema- IN ADULTS WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES MELLITUS.pptx Curious about the latest breakthrough

Oral semaglutide for weight loss is designed for adults merging this treatment with a reduced-calorie diet and increased physical activity

Human trials are ongoing, particularly in the context of aging, Alzheimers disease, and cancer

Silvestrini, A., Meucci, E., Ricerca, B

Mounjaros dual action on both GLP-1 and GIP receptors enhances its ability to control blood sugar, often leading to better outcomes than older medications

European Commission 21 januari 2022 GLP-1 approved for the treatment of obesity in EU The European Commission has approved GLP-1 for chronic weight management in adults with obesity FDA Juni 2021 FDA Approves New Drug Treatment Voor het eerst sinds 2014 keurt de FDA een nieuwe afslankmethode goed